---
title: "Amgen Says Strongly Disagrees With FDA'S Proposal To Withdraw Tavneos From The U.S. Market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293755129.md"
datetime: "2026-07-24T12:13:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293755129.md)
  - [en](https://longbridge.com/en/news/293755129.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293755129.md)
---

# Amgen Says Strongly Disagrees With FDA'S Proposal To Withdraw Tavneos From The U.S. Market

July 24 (Reuters) - Amgen Inc (AMGN.O) : \* AMGEN : SUBMITS DATA TO FDA SEEKING HEARING ON TAVNEOS AVACOPAN IN RESPONSE TO WITHDRAWAL PROPOSAL \* AMGEN INC: STRONGLY DISAGREES WITH FDA'S PROPOSAL TO WITHDRAW TAVNEOS FROM THE U.S. MARKET Source text: Further company coverage: (AMGN.O)

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

- [Amgen says EU CHMP backs broader Repatha use to cut first heart attack, stroke risk](https://longbridge.com/en/news/294212406.md)
- [Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings](https://longbridge.com/en/news/291188646.md)
- [Amgen taps research firm to reassess Tavneos data](https://longbridge.com/en/news/289522929.md)
- [Amgen's $500 Million Tavneos Faces FDA Withdrawal Fight](https://longbridge.com/en/news/289602804.md)
- [Shein clears Hong Kong listing hearing as Q1 growth slows to 1.1%](https://longbridge.com/en/news/293937724.md)